TCG Crossover Management LLC Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)

TCG Crossover Management LLC bought a new stake in Upstream Bio, Inc. (NASDAQ:UPB) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,801,763 shares of the company’s stock, valued at approximately $44,856,000. Upstream Bio accounts for about 4.4% of TCG Crossover Management LLC’s portfolio, making the stock its 7th largest holding. TCG Crossover Management LLC owned 0.05% of Upstream Bio as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in UPB. FMR LLC bought a new stake in shares of Upstream Bio during the fourth quarter valued at approximately $117,977,000. Decheng Capital LLC bought a new stake in Upstream Bio during the 4th quarter valued at $54,010,000. Bain Capital Life Sciences Investors LLC acquired a new position in Upstream Bio during the 4th quarter worth $37,735,000. Wellington Management Group LLP bought a new position in shares of Upstream Bio in the fourth quarter worth $25,632,000. Finally, Alliancebernstein L.P. acquired a new position in shares of Upstream Bio during the fourth quarter valued at $18,270,000.

Upstream Bio Stock Up 4.6 %

UPB stock opened at $8.78 on Tuesday. The company has a 50-day simple moving average of $7.88 and a 200 day simple moving average of $14.41. Upstream Bio, Inc. has a fifty-two week low of $5.14 and a fifty-two week high of $29.46.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.